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Classical inflammation is a well-characterized secondary response tomany acute disorders of the central nervous system. However,
in recent years, the role of neurogenic inflammation in the pathogenesis of neurological diseases has gained increasing attention,
with a particular focus on its effects on modulation of the blood-brain barrier BBB.The neuropeptide substance P has been shown
to increase blood-brain barrier permeability following acute injury to the brain and is associated with marked cerebral edema. Its
release has also been shown to modulate classical inflammation. Accordingly, blocking substance P NK1 receptors may provide
a novel alternative treatment to ameliorate the deleterious effects of neurogenic inflammation in the central nervous system. The
purpose of this paper is to provide an overview of the role of substance P and neurogenic inflammation in acute injury to the central
nervous system following traumatic brain injury, spinal cord injury, stroke, and meningitis.
1. Introduction
Acute disorders of the central nervous system (CNS), includ-
ing traumatic brain injury (TBI), spinal cord injury (SCI),
stroke, and meningitis, account for a significant disease
burden worldwide, with CNS injury being the leading cause
of death after trauma [1].These acute neurological conditions
affect individuals of all ages and both sexes alike resulting in
significant morbidity and mortality. Despite the prevalence
of these conditions, current treatments remain limited and
largely inadequate. New therapies are urgently required in
order to reduce the death and disability associated with these
conditions. One feature which is central to each of these con-
ditions is disruption to the blood-brain barrier (BBB)/blood-
spinal cord barrier (BSCB) and subsequent development
of vasogenic edema. As such, targeting this aspect of the
injury cascade is likely to produce beneficial outcomes in
each of these conditions. Recent reports on the role of the
neuropeptide substance P (SP) and neurogenic inflammation
in BBB dysfunction and genesis of cerebral edema following
acute brain injury suggest that this pathway provides a
novel target for therapeutic intervention. The current paper
will provide an overview of the BBB and vasogenic edema,
followed by a discussion of the role of SP and neurogenic
inflammation in CNS injury.
2. Blood-Brain Barrier/Blood-Spinal
Cord Barrier
The BBB is a highly selective barrier that serves to protect the
fragile brain microenvironment. It is the interface between
the blood and the brain, separating the brain parenchyma
from the blood within cerebral capillaries, and involves the
interactions between endothelial cells, astrocytes, pericytes,
and the capillary basement membrane. Within the spinal
cord, the blood-spinal cord barrier (BSCB) is similar in
function to the BBB [2] and serves to protect the spinal
cord by modulating the entry of blood-borne substances.
The fundamental structures of the BBB and BSCB are the
same although there are some specific differences in the
BSCB including glycogen deposits, decreased P-glycoprotein
transporters, and decreased expression of tight junctional
protein expression [3].
The main function of these barriers is to facilitate a
constant supply of nutrients, preserve ion homeostasis within
the brain/spinal cord microenvironment, and protect against
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noxious chemicals, variations in blood composition, and the
breakdown of concentration gradients. The gate function
of the BBB and BSCB is afforded by tight and adherens
junctions, comprised of a complex network of transmem-
brane and cytosolic proteins [4, 5]. Specifically, claudins,
occludins, junctional adhesion molecules (JAMs), and zona
occludens (ZOs) are the proteins that make up this network.
Tight junctions are located on the most apical region of the
cleft between cerebral capillary endothelial cells and form
a seal to prevent substances from passing between them
[6]. Claudins, predominately caludin-5, are involved in the
primary makeup or backbone of tight junctions, forming
dimers which interact with opposing claudin molecules to
form the primary seal of the tight junction [6, 7]. JAM has
a single transmembrane segment, which initiates cell-to-cell
attachment and is able to mediate permeability through this
avenue [7]. Occludin has four transmembrane segments and
is present in higher concentrations in endothelial cells of
the BBB than in those in systemic capillary endothelial cells.
It induces high membrane resistance, which is indicative
of low ion permeability [7, 8]. Occludin interacts with the
cytoskeleton of BBB/BSCB endothelial cells through ZO1,
ZO2, and ZO3 molecules [6, 7]. A further obstacle to prevent
the entry of unwanted substances into the brain is provided
by the basement membrane of the BBB, which is made up of
proteins found within the extracellular matrix including col-
lagens, vitronectin, fibronectin, tenascin, and proteoglycans
[9]. These components provide stability to the structure of
the blood vessels and a surface upon which cerebral capillary
endothelial cells can rest.
Astrocytes are central to the structure and function of the
BBB/BSCB. Their end feet surround 99% of BBB endothelial
cells and act to support and enhance the tight junctions
between them [7, 10]. Furthermore, astrocytes mediate the
connection between neurones and endothelial cells [11], and
the gap junctions between astrocytes allow for quick transfer
of substances and information [12].They become activated in
response to pathological stimuli, which results in the hyper-
trophy of the astrocytic processes and overexpression of inter-
mediate filaments, namely, glial fibrillary acidic protein [12].
Pericytes have a stellate appearance and cytoplasmic
processes and act as support cells that play an important role
in the BBB/BSCB.They cover 22–32% of the capillary cell sur-
faces [13], and the gap junctions between pericytes and cere-
bral capillary endothelial cells allow communication to occur
[7]. The main function of pericytes is thought to be blood
flow regulation, particularly in the precapillary arterioles that
supply the brain with blood [14]. The structure of pericytes
makes them ideal for this function, as they are contractile and
express the smooth muscle actin isoform [13]. Collagen type
IV glycosaminoglycans and laminin are also synthesised in
pericytes to be used in formation of the basement membrane
[13]. They have the ability to regulate endothelial cell prolif-
eration, survival, migration, and differentiation [7].
3. Edema
Of the secondary injury factors that occur in the setting
of CNS injury, edema within the brain or spinal cord is
of particular concern given its association with increased
mortality and morbidity [15, 16]. Edema is defined as the
abnormal accumulation of fluid within the CNS tissue.
Klatzo [17] was the first to classify edema into two broad
categories based upon the integrity of the BBB: cytotoxic and
vasogenic edema. Cytotoxic edema is an intracellular edema
that occurs as a result of cellular injury. It is characterized
by a shift of water from the extracellular compartment to the
intracellular compartment, accompanied by shrinkage of the
extracellular space. Cytotoxic edema occurs independently
of alterations in the BBB/BSCB and appears to be more
prominent in the grey matter [18]. Failure of the Na+/K+
ATPase in regions of energy failure and subsequent loss of
ion homeostasis, leading to influx of water into cells, is central
to the development of cytotoxic edema [19, 20]. Conversely,
vasogenic edema has been shown to be more prevalent in
the white matter [18] and involves the escape of proteins
from the vasculature in the setting of BBB/BSCB disruption
and injury to cerebral blood vessels. Protein accumulation in
the brain/spinal cord extracellular space causes an osmotic
increase at the site of injury and the subsequent movement of
water down its osmotic gradient.There is a strong correlation
between extravasation of proteins into the extracellular space
and the development of vasogenic edema [21, 22].
The temporal profile of edema pathogenesis after injury
varies greatly with injury type and severity [23] and has
been extensively studied in order to characterize the period
in which anti-inflammatory pharmacological interventions
may be effective. In a mouse model of cerebral contusion,
permeability of the BBB to large proteins was resolved by
approximately 5 hours following injury, whereas smaller
molecules of 10 kDa were still able to pass through the BBB
for up to 4 days [24]. Similarly, the BSCBmay be disrupted for
several days following traumatic SCI [25, 26]. Furthermore,
in ischemic stroke, it has been shown that edema continues
to develop for up to 7 days, with the initial cytotoxic edema
being followed by vasogenic edema [27]. Thus, there is
substantial opportunity for amelioration of barrier dysfunc-
tion and subsequent cerebral edema through manipulation
of mediators of BBB/BSCB permeability. Further studies
are required to elucidate the exact mechanisms of barrier
disruption and subsequent edema pathogenesis to develop
targeted therapeutic agents.
The development of edema is associated with significant
mortality and morbidity in the setting of CNS injury. Such
outcomes are related to the ability of vasogenic edema to
lead to an increase in pressure within the cranium or spinal
canal. Given that the skull is rigid structure, any increase in
the intracranial contents (blood, brain, and cerebral spinal
fluid)must be compensated by a decrease in the volume of the
other components.The same is truewithin the spinal column.
Within both the brain and the spinal cord, there is limited
capacity for compensation through reductions in blood or
cerebrospinal fluid volume to accommodate for an increase in
the intracranial volume.This compensation is responsible for
the initial plateau in the intracranial pressure/volume curve,
which becomes exponential once compensatorymechanisms
are exhausted [28]. When such compensatory mechanisms
fail, profound increases in intracranial pressure (ICP) or
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intrathecal pressure (ITP) may result. The sequelae of ele-
vated ICP/ITP include reduced blood flow to CNS tissue,
ischemia and infarct extension, deformation and herniation
of the brain and spinal cord tissue, and in severe cases, death
[18, 29–31].
With the mortality of malignant cerebral edema approa-
ching 80% [18], the reduction of cerebral edema and its
associated rise in ICP is now widely recognised as an impor-
tant clinical management target. Current treatments seek
to reduce brain swelling and ICP though administration of
hyperosmotic agents and barbiturates, induction of hyper-
ventilation or hypothermia, and surgical interventions such
as cerebrospinal fluid (CSF) drainage, or in severe cases,
decompressive craniectomy [23, 30, 32, 33]. In the case of
hemorrhage, evacuation of space occupying lesions like
hematomas may be warranted [34]. Clinical signs of edema
have been linked with poor functional outcome following
SCI [16]. The use of steroids in an attempt to minimize SCI-
induced edema and inflammation is common, despite the
controversy surrounding their effectiveness and safety [35].
Decompressive surgery is also a current standard treatment
following SCI [36].
With respect to patient morbidity and mortality, current
clinical treatment regimens for acute disorders of the CNS
have proven somewhat ineffective, mainly because they do
not address the specific mechanisms that are associated with
the genesis of edema in cerebral ischemia. Recent studies have
identified substance P (SP) release as a feature of acute CNS
injury and have delineated a critical role for SP in increased
BBB permeability and the development of vasogenic edema.
4. Neurogenic Inflammation
Neurogenic inflammation is a neurally elicited, local inflam-
matory response characterized by vasodilation, increased
vascular permeability, mast cell degranulation, and the
release of neuropeptides including SP and calcitonin gene-
related peptide (CGRP) [37]. In addition, there are also
tissue-specific responses including smooth muscle contrac-
tion/relaxation in the bladder and bronchoconstriction in the
airways, amongst others [38]. Neurogenic inflammation has
been demonstrated in tissue receiving trigeminal innervation
andmay be stimulated bymany agents including prostanoids,
leukotrienes, histamine, and serotonin, as well as by changes
in the extracellular environment such as decreased pH,
increased osmolarity, heat, inflammatory conditions, and
tissue (mechanical) injury [39, 40]. The changes in blood
vessel size and permeability that occur with neurogenic
inflammation lead to edema formation within the tissue
[21, 22]. Perhaps the most important factor in this response
is SP, having been identified as the most potent initiator of
neurogenic inflammation [41, 42].
Neurogenic inflammatory mediators such as SP and
CGRP and their respective receptors are found in abundance
in both the rodent and human CNSs, and whilst neu-
rogenic inflammation and classical inflammation are both
inflammatory processes, neurogenic inflammation in the
brain differs from classical inflammation in that neurogenic





































+ ↓ cerebral blood flow




Figure 1: Acute CNS injury leads to the initiation of both neuro-
genic inflammation and classical inflammation.
permeability of the BBB through the release of neuropeptides.
In contrast, classical inflammation involves the accumulation
and proliferation of microglia, perivascular macrophages,
and other inflammatory cells (Figure 1) [43, 44]. These cells
subsequently release classical inflammatory mediators like
bradykinin, which drive vascular changes [45]. Nevertheless,
there is an interaction between the two processes as many
of the factors within each cascade may initiate or potentiate
the other. For example, the classical inflammatory mediator
bradykinin causes release of the neurogenic inflammatory
mediator SP, which in turn is well known to cause mast
cell degranulation along with bradykinin and nitric oxide
release by endothelial cells and thus potentiation of classical
inflammation (Figure 1). Inflammation in the brain may play
many roles, including the maintenance of tissue homeostasis,
although when these processes are unable to be controlled,
tissue damage occurs. Thus, this paper focuses on the phar-
macological blockade of neurogenic inflammation for the
treatment of acute disorders of the CNS.
There aremultiple pathways by which neurogenic inflam-
mation may be initiated. It is well documented, using both































intracellular calcium ions, CGRP—calcitonin gene-related peptide,
SP—substance P, CRLR—calcitonin receptor-like receptor, RAMP—
receptor activity modifying protein, NK1—NK1 receptor, EC—
endothelial cell.
animal models and isolated neurons in vitro, that capsaicin,
heat, protons, bradykinin, and tryptase are upstream reg-
ulators of the intracellular calcium influx, which results in
inflammatory neuropeptide release [46–48]. In contrast, it is





1, interleukin-6, and tumor necrosis factor do not cause neu-
rotransmitter release themselves, but rather excite sensory
neurons and thus lower the threshold for firing and cause
augmented release of neuropeptides [48, 49].
While neurogenic inflammation has been extensively
studied and well documented in peripheral tissues [50,
51], until recently the concept of neurogenic inflammation
within the CNS has remained largely unexplored. Given the
capacity for neurogenic inflammation to influence vascular
permeability and lead to the genesis of edema (Figure 2), it
has now been widely investigated for its potential to influence
BBB permeability and vasogenic edema within the brain and
spinal cord under varying pathological conditions.
4.1. Capsaicin. Capsaicin activates transient receptor poten-
tial vanilloid-1 (TRPV1) channels on polymodal nociceptive
fibers, thus, resulting in the release of neurogenic inflamma-
tory mediators and subsequent vasodilation and increased
vascular permeability [52, 53]. Under experimental condi-
tions, capsaicin is commonly used to cause release and/or
depletion of neuropeptides [54]. Thus, capsaicin initially
elicits a neurogenic inflammatory response, followed by a
refractory period in which there is no response to factors
that would ordinarily induce neurogenic inflammation. At
high doses in young animals, capsaicinmay cause permanent
damage to the sensory neurons so that neurogenic inflamma-
tory mediators are no longer synthesized, meaning that the
neurogenic response is permanently abolished.
4.2. Substance P. SP is an 11 amino acid peptide that is amem-
ber of the tachykinin family, so named for their fast-acting
properties [55], which also includes neurokinin A (NKA),
neurokinin B (NKB), neuropeptide K (NPK), and neuropep-
tide 𝛾 (NP𝛾), amongst others. SP is released fromboth central
and peripheral endings of primary afferent neurons where it
functions as a neurotransmitter [41, 55]. SP, along with other
tachykinins, is produced from the preprotachykinin (PPT) A
and B genes. Alternate splicing of the PPTA gene yields the
𝛼- and 𝛿-transcripts giving rise to SP, NKA, NPK, and NK𝛾,
whereas the 𝛽- and 𝛾-transcripts only produce SP. The PPTB
gene only encodes for NKB. SP synthesis occurs at the cell
body ribosomes, where it is then packaged into vesicles and
axonally transported to the terminal endings for final enzy-
matic processing [56]. Precursor proteins are stored in secre-
tory granules along with processing enzymes for posttransla-
tional modifications and release of the active peptide [39, 57].
The biologically active peptide is then stored in large, dense
vesicles ready for release. Under normal conditions, substan-
tial amounts of SP are synthesised and stored within neurons
[56]. However, activation or damage of these neurons results
in the rapid release of SP and other neuropeptides [39].
SP is widely distributed throughout the central and peri-
pheral nervous systems, with 𝛼-PPTA transcriptsmore abun-
dant within the brain and𝛽-PPTA transcriptsmore abundant
in peripheral tissues. Specifically, in the brain, SP immunore-
activity has been demonstrated in the rhinencephalon, telen-
cephalon, basal ganglia, hippocampus, amygdala, septal
areas, diencephalon, hypothalamus, mesencephalon, meten-
cephalon, pons, myelencephalon, and spinal cord. SP has
also been found localized within brain endothelial cells and
microglia [58–60]. In peripheral tissues, SP and other sensory
neuropeptides are distributed throughout the gut, respiratory
system, urinary system, immune system, blood, and blood
vessels [37]. SP is localized in capsaicin sensitive neurons and
is released from central and peripheral endings of primary
afferent neurons in response to various noxious stimuli [39].
Of interest is the fact that SP is colocalizedwith other classical
transmitters such as serotonin and glutamate, and other
neuropeptides such as CGRP and NKA [56, 59].
Once released, SPmay be cleared and inactivated bymany
different proteolytic enzymes including neutral endopep-
tidase (NEP) [61, 62] and angiotensin-converting enzyme
(ACE) [61, 63, 64], amongst others. BothNEP andACE catal-
yse the degradation of the hydrolytic bonds of SP, rendering it
inactive without the carboxyl terminus required to bind to its
receptor [56]. Specifically, NEP has been shown to degrade SP
within the brain [65], spinal cord [66], and peripheral tissues
[39], whereas ACE has been shown to degrade SP in plasma,
CSF, and brain, in particular the substantia nigra [67].
The biological actions of SP are mediated through its
binding at tachykinin NK receptors which are rhodopsin-
like membrane structures comprised of 7 transmembrane
domains connected by intra- and extracellular loops and
coupled to G proteins [68]. To date, 3 mammalian tachykinin
receptors have been identified, theNK1,NK2, andNK3 recep-
tors [69].The tachykinins share a common carboxyl terminal
sequence that reflects their common biological action, and, as
a result, some cross-reactivity amongst tachykinin receptors
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exists [70]. Each of the tachykinins may act on all receptor
types with varying affinities depending upon receptor avail-
ability and neuropeptide concentration. Under normal con-
ditions, SP has a high affinity for the NK1 receptor, NKA for
the NK2 receptor, andNKB for the NK3 receptor [38, 71].The
NK1 receptor is a 403 amino acid protein that is highly con-
served with only discrete variations amongst species. AnNK1
autoreceptor has also been characterized to be involved in
the regulation of SP release [72–75]. NK1 receptors are found
in their highest levels in the caudate putamen and superior
colliculus; however, they are also found in low to moderate
levels in the inferior colliculus, olfactory bulb, hypothalamus,
cerebral cortex, septum, striatum,mesencephalon, and dorsal
horn of the spinal cord [75]. NK1 receptors are expressed
by a wide variety of cell types including neurons, astrocytes,
oligodendrocytes, endothelial cells, and microglia [76].
SP release is initiated in response to Ca2+-dependent dep-
olarisation of neurons, induced by a variety of stimuli includ-
ing electrical stimulation, pH changes, and ligand binding to
their receptors, including capsaicin [37, 57]. Once released,
SP has several effects including direct postsynaptic actions
as a neurotransmitter, modulatory function at postsynaptic
sites, and/or paracrine functions on nonneuronal targets [57].
Transduction of the SP signal then occurs through the action
of G proteins associated with the intracellular domain of the
NK1 receptor, leading to an elevation in cAMP as a secondary
messenger, which through a cascade of events, leads to the
regulation of ion channels, enzyme activity, and changes in
gene expression [48, 77]. Although normally confined to the
cell membrane, the NK1-SP complex is rapidly internalised
following SP binding. SP is then removed by endosomal
acidification and targeted by the lysosomes for degradation,
whilst the NK1 receptor is recycled to the cell membrane [57].
In addition to its role in neurogenic inflammation, SPmay
induce classical inflammatory reactions through the release
of cytokines and recruitment of immune cells. In the skin, SP
acts in a dose-dependant fashion to induce mast cell degran-
ulation and histamine and tumour necrosis factor-𝛼 along
with variable release of leukotriene B4 [78, 79]. SP also acts
to induce widespread microvascular permeability. Virtually
all blood vessels are surrounded by primary sensory nerve
fibers that secrete SP, and the cerebral blood vessels are partic-
ularly well innervated. Intravenous injection of SP has been
shown to increase the permeability of dural blood vessels as
evidenced by leakage of horseradish peroxidase in association
with widening of junctions between endothelial cells and an
increase in the number of cytoplasmic vesicles [80].
In brain endothelial cells, the normal resting level of free
Ca2+ is 100 nM [81]. SP causes calcium responses in the endo-
thelial cells of the BBB of approximately 1000 nM and hence
increase Ca2+ levels leading to increased BBB permeability
through cell contraction [81, 82]. In conjunction with this,
treatmentwith SP of cerebral capillary endothelial cells cocul-
tured with astrocytes has been shown to decrease the con-
centration of ZO-1 and claudin-5 tight junctional proteins,
resulting in increased permeability of the simulated BBB [83].
SP is present in cerebral capillary endothelial cells, and its
secretion by these cells can be increased through treatment
with high doses of cytokines, including interleukin-1𝛽 and
tumour necrosis factor 𝛼 [60, 84].This increase in SP released
from brain endothelial cells was found to be associated
with an increase in the expression of 𝛽-preprotachykinin
mRNA, a precursor for SP, inside the cells [60]. Spantide, a
NK1 antagonist, reversed this increase in SP release from
endothelial cells and the subsequent increased permeability
of the BBB in a dose-dependent fashion [84].Through the use
of electron microscopy, it was shown that the morphological
changes associated with SP interactions with endothelial cells
were also neutralized [84].
SP has been implicated in the pathogenesis of many
neurological diseases, due to its effects on BBB permeability.
Thus, NK1 antagonists have been investigated for the treat-
ment of chronic diseases such as Parkinson’s [85], depression
[86], brain tumours [43, 87, 88], and migraine [89] with
variable success. However, this paper focuses primarily on
acute disorders of the CNS.
The only NK1 receptor antagonist that is currently avail-
able and approved for use clinically is aprepitant. This drug
is used as an antiemetic to combat chemotherapy-induced
nausea in cancer patients and is generally well tolerated [90].
Thus, NK1 receptor antagonist treatment is an appealing
alternative to classical anti-inflammatory drugs, the use of
which are often limited by detrimental side effects for the
treatment of acute and chronic CNS diseases.
4.3. Calcitonin Gene-Related Peptide. CGRP is a neuropep-
tide that is commonly colocalized and released with SP,
particularly within sensory C fibers that innervate cerebral
vasculature [91–94]. CGRP is the most potent endogenous
vasodilator [95] and has been shown to increase the diameter
of large cerebral arteries and arterioles. This vasodilation has
been shown in many species, including the carotid arterial
bed of rabbits, piglet arterioles, pial artery of cats, and guinea
pigs [96–99]. Furthermore, CGRP infusion in healthy human
subjects causes middle meningeal artery dilation [100]. The
relaxation of blood vessels by CGRP is mediated by protein
kinase C [101]. There are two isoforms of CGRP, CGRP𝛼
and CGRP𝛽, which are encoded by alternate RNA processing
of the gene for calcitonin located on chromosome 11 and
CGRP𝛽 [102, 103]. These isoforms differ in only a single
amino acid and are functionally similar, although CGRP𝛼 is
the predominate form found in the CNS [104]. CGRP exerts
its function through binding at theCGRP receptor, which like
the NK1 receptor, has seven transmembrane domains and is
coupled to a G protein. The receptor interacts with a single
transmembrane receptor activity modifying protein to allow
for activation to occur [105, 106]. These receptor complexes
are commonly located on neurons, astrocytes, smoothmuscle
cells, and endothelial cells, particularly those lining dural
blood vessels [107–109]. CGRP potentiates the actions of SP
[110], which is thought to be through interference with SP
breakdown processes [111, 112].
5. Traumatic Brain Injury
TBI results from physical trauma to the head that conse-
quently causes injury to the brain. It is currently the leading
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cause of death in individuals under the age of 45 years,
with an incidence range of 100–3000 per 100,000 and death
rates reported as approximately 18.4 per 100,000 [113–118].
Secondary injury, defined as the persisting alterations to
chemicals, cells, and metabolism in the hours and weeks
following the primary injury to the brain, is thought to be
responsible for substantial cerebral edema and development
of neurological deficits [119]. This is of great importance as
cerebral edema has previously been shown to be a significant
predictor of TBI-induced mortality [15, 18].
The majority of TBI cases can be attributed to motor
vehicle accidents, motorcycle accidents, bicycle accidents,
and pedestrian injuries [120]. Survivors are often are left
with debilitating neurological deficits after injury [121, 122],
so in addition to the enormous personal burden to victims
and their families, the financial impact for the community
in terms of hospitalization, treatment, rehabilitation, and
specialized care runs into the billions of dollars annually.
Despite improvements in motor vehicle safety measures and
the marginal decrease in the mortality of trauma-related
pathologies [123], TBI still has a significant epidemiological
and economic burden on society [124].
Outcome following motor vehicle accident-induced tra-
uma is superior in comparison with patients who experience
CNS trauma as a result of a fall, likely due to the advanced
age generally seen in people who are injured through falling
and the younger demographic involved in traffic accidents
[125]. Factors that have been implicated in determining the
prognosis for patients include age,GlasgowComaScale score,
arterial hypotension, computed tomography findings, and
pupillary reactivity [126]. Childhood populations of trauma
victims with evidence of cerebral edema on neuroimaging
have shown significantly poorer outcome [15]. Despite this
devastating impact, there is currently no approved therapy
for the treatment of head trauma, largely because the mecha-
nisms associated with neuronal cell death and the develop-
ment of cerebral edema are poorly understood. Therefore,
recent studies have focused on ameliorating cerebral edema
in an attempt to improve recovery following trauma.
TBI results from acceleration/deceleration forces that
produce rapid movement of the brain within the skull, or
from the head impacting with an object form. The type
and severity of the resultant injury are dependent upon the
nature of the initiating force, in addition to the site, direction
and magnitude of the impact. Injury to the brain following
TBI may arise from two different mechanisms, designated
as primary and secondary injuries. Primary injury is irre-
versible, occurring at the time of impact and encompassing
themechanical forces at the time of injury that damage blood
vessels, axons, neurons, and glia through shearing, tearing,
and stretching [127]. It also includes surface contusions
and lacerations, diffuse axonal injury, and hemorrhage. The
shearing forces applied to neurons in response to injury cause
massive ion fluxes across neuronal membranes, resulting in
the widespread loss of membrane potential and the excessive
release of neurotransmitters [128]. Such cellular events are
part of an evolving sequence of cellular, neurochemical, and
metabolic alterations termed as secondary injury, which is
initiated by the initial traumatic events and ensues in the
hours to days following the initial traumatic event. Secondary
injury has profound effects on ion channels, membranes,
intracellular biochemical events, and second messenger sys-
tems and includes changes in neurotransmitter release, ion
homeostasis, blood flow, and cellular bioenergetic state, along
with oxidative stress and lactoacidosis [129]. Infiltration of
the brain and perilesional area by neutrophils, macrophages,
and microglia is also a characteristic of secondary injury and
inflammation [130]. Unlike primary injury, such secondary
injury is potentially reversible, because its delayed nature
provides a therapeutic window for pharmacological inter-
vention. The aim of such therapy is to reduce injury and
improve both outcome and survival. However, despite the
large number of experimental studies successfully targeting
individual injury factors, none have resulted in an effective
therapy that can be used clinically.
Substance P in Traumatic Brain Injury.Traumatic brain injury
is associated with significant edema formation, proposed
by our own group to be mediated by SP and thus neurog-
enic inflammation. In the human postmortem tissue, SP
immunoreactivity is increased following traumatic brain
injury [131]. Similarly, perivascular SP immunoreactivity was
increased in a rat model of brain trauma, which was closely
associated with increased Evans blue leakage into the neu-
ropil, commonly used as an exogenous marker of increased
BBB permeability [132]. Animals chronically pretreated with
capsaicin, an agent shown to deplete neuropeptides, sig-
nificantly reduced BBB permeability, cerebral edema, and
functional deficits as compared to vehicle-treated controls
in a rodent model of diffuse traumatic brain injury [133].
Likewise, NK1 antagonist treatment has been shown to
reduce BBB permeability and cerebral edema and to improve
functional outcome in this model [132, 134]. Similarly, this
treatment has also resulted in amelioration of the proliferative
microglial response to diffuse traumatic brain injury [135].
Prevention of SP breakdown with ACE inhibitor treatment
also resulted in increased evidence of trauma-induced his-
tological damage and exacerbation of neurological deficits
[136].
Most of these studies investigating the effects of NK1
antagonist treatment following diffuse traumatic brain injury
have been performed in male rats. This is because estro-
gen may provide additional neuroprotection in females,
which could confound experimental results. However, it is
important that drugs to treat the complications following
traumatic brain injury be effective in both sexes. Recently,
an NK1 antagonist treatment has been investigated in an
experimental model of trauma in female rats and has been
shown to similarly reduce BBB permeability and cerebral
edema following injury [137].
Together, these findingsmake a strong argument for links
between elevated perivascular SP and increased BBB perme-
ability leading to cerebral edema formation following both
experimental and clinical traumatic brain injuries.Therefore,
NK1 antagonist treatment may be beneficial for patients with
traumatic brain injury in relieving symptoms of cerebral
edema and improving recovery.
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6. Traumatic Spinal Cord Injury
Spinal cord injury (SCI) is an insult to the spinal tissue that
results in altered motor, sensory, and autonomic functioning.
The incidence and mortality estimates for SCI range from 1.3
to 8.3 per 100,000 and 0.3–1.8 per 100,000, respectively, which
is approximately 10% of the rates reported for TBI [138–140].
Common mechanisms of SCI are vertebral dislocation and
burst fracture injury [141]. Similar to TBI, initial primary
injuries including laceration of blood vessels, bone fracture,
and axonal injury, are followed by persistent secondary
inflammatory processes. Specifically, this commonly includes
immune cell accumulation and inflammatory mediatory
release, which have been linked to BSCBdisruption [142, 143].
The BSCB controls the passage of substances between capil-
laries and spinal tissue and is disrupted to cause vasogenic
edema [144]. This increased permeability of the BSCB may
be evident over several segments rostral and caudal from
the injury epicenter, particularly following severe spinal cord
injury [25, 26]. The importance of this process is illustrated
by the established link between edema formation and SCI-
induced mortality [16].
Nearly 80% of spinal trauma occurs in males, with two
peak age groups affected, young adults in their 20s and
the elderly over 60 years of age. This bimodal demographic
is thought to be associated with traffic accidents and falls,
respectively [145]. Brain injury is a common comorbidity
for spinal trauma, which is unsurprising as it has many
common epidemiological features. The most common site
of traumatic spinal cord injury is the cervical level, with
decreasing incidence in the lumbar and thoracic regions of
the cord [146]. The clinical deficits increase in severity as the
SCI occurs at a higher, or more superior, level.
Spinal cord injury is a highly inflammatory process,
resulting in immune cell chemotaxis. In a rodent model
of thoracic contusion, inflammatory cytokine release was
evident in the spinal cord following injury, which replicates
the human condition where a similar pattern of cytokine
expression was evident in the CSF, although at a later time
point [147]. Additionally, following T9 spinal contusion,
neutrophil, macrophages/microglia, and T cells infiltrate the
injured spinal cord and remain evident up to 180 days
following trauma [148].
The promising research on the role of SP in edema
development following brain trauma has led researchers to
consider that the pathogenesis of secondary injury following
spinal cord injury may have similar mechanisms. Moreover,
it is thought that this injury type may too respond to manip-
ulation of inflammatory neuropeptides, as it has previously
been shown that resolution of BSCB permeability and edema
results in improved functional outcome in animal models of
SCI [149, 150].
Neurogenic Inflammation in Spinal Cord Injury. Previous
studies have shown that SP expression is altered following
traumatic SCI in both the human condition and in experi-
mental animal models. In a combined human cohort of both
peripheral nerve and SCI patients, increased SP levels in the
cerebrospinal fluidwere observed in comparisonwith control
patients [151]. Similarly, at both 1 and 2 hours after focal
thoracic injury, there was a significant increase in SP found
up to 5mm from the site of injury [152]. In addition, there
was a significant increase in brain SP 5 hours after injury
[152]. Therefore, the modulation of SP following trauma to
the spinal cord may occur throughout the entire CNS. There
was also an increase in SP evident following T12 transection
of the spinal cord in female cats [153]. In contrast, a weight
drop model of trauma in rodents resulted in decreased SP at
the site of injury [154]. Furthermore, NK1 receptors have been
shown to be significantly increased 1 week after injury using a
ratmodel of thoracic cordotomy [155].The alterations in both
SP and NK1 receptor expression in the spinal cord following
trauma suggest that SP may play a part in the pathogenesis
of spinal cord injury and its complications. However, further
studies are required to determine its exact role.
There has been limited research on the role of CGRP in
traumatic spinal cord injury. It has been shown, following
either C4 or T13 hemisection, that primary afferents axons
immunostaining for CGRP grow into the area of injury [156,
157]. However, the functional or mechanistic significance of
this is yet to be elucidated. Therefore, the evidence for a
role of CGRP and possible therapeutic benefit following its
manipulation is far less compelling for spinal injury when
compared to the results seen for other pathologies.
7. Stroke
Stroke is the third most common cause of disability-adjusted
life years and as such is a major health problem worldwide
[158]. Specifically, a staggering 15 million people worldwide
suffer a stroke each year, of which 10 million either die or
are left permanently disabled [159]. The social and economic
costs of stroke are consequently enormous. Despite this,
there is currently only one approved treatment for use in
stroke, that being tissue plasminogen activator within 4.5 h
of symptom onset [160]. However, as little as 5–15% of stroke
patients are eligible for and receive such treatment. In the case
of hemorrhagic stroke, little can be done beyond evacuation
of the hemorrhage if surgically accessible. As such, novel
therapies that can limit or reverse ischemic injury following
stroke are urgently required.
Stroke is defined as an interruption in the cerebral blood
flow of vascular origin that restricts the supply of vital oxygen
and substrates for neurons. Stroke can be broadly classified
into two types, ischemic and hemorrhagic. Ischemic stroke
most frequently involves a thrombus (local origin) or embo-
lus (distant origin) obstructing blood flow, although when
blood flow is reestablished, reperfusion injury may occur.
This involves the interaction of blood with oxygen-deprived
tissue resulting in substantial inflammation and oxidative
stress. Hemorrhagic stroke refers to a bleed within the brain.
In both instances, cerebral ischemia results, and if blood
flow is not rapidly restored, death of cells may result with
associated long-term functional deficits [161]. Restoration of
blood flow is seen as an urgent priority in reducing the
extent of tissue injury and preserving function. However, it is
now well accepted that secondary injury processes continue
to evolve many hours to days following stroke and also
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contribute to the size of the infarct [162]. With respect to
outcome, hemorrhagic stroke generally has a poorer outcome
than ischemic stroke with mortality rates in the order of
37% and 11%, respectively [163]. Hemorrhagic stroke may
be classified as either intracerebral hemorrhage (ICH) or
subarachnoid hemorrhage (SAH). The rupture of charcot-
bouchard microaneurysms on small arterioles commonly
leads to ICH, whereas ruptured berry aneurisms within the
Circle of Willis are often the cause of SAH [164, 165].
Following stroke, the resultant tissue injury and infarc-
tion can be considered as being made up of two components,
the infarct core and the surrounding penumbral tissue [166].
The infarct core is widely considered to be irreversibly
damaged during ischemic stroke, with cell death occurring
rapidly within this region. In the penumbral tissue, however,
blood flow is less restricted and so there exists an opportunity
for neuronal tissue to survive the insult. Nevertheless, cell
death may continue to occur here as a result of secondary
biochemical and physiological mechanisms that manifest
over the hours to days following stroke [162, 166]. Similar to
TBI, there are diverse arrays of secondary injury processes
that contribute to injury and cell loss following stroke, includ-
ing excitotoxicity, oxidative stress, inflammation, apopto-
sis, increased vascular permeability, and cerebral edema,
amongst others [167]. Given the delayed nature of secondary
injury following stroke, there is an opportunity for pharma-
cological intervention to limit tissue damage and cell death.
Both SAH and ICH can often result in rapid death,
meaning that there is only a small window for therapeutic
administration or surgical intervention. Furthermore, given
that themass effect of such hemorrhagic lesions is substantial,
the contribution of secondary injury processes to functional
impairments is smaller compared with ischemic lesions.
In contrast, ischemic stroke has a pattern of injury more
comparable to TBI, with increased permeability of the BBB
and cerebral edema as common features. Mortality rates
increase with time following stroke, demonstrating that even
if patients survive the initial insult, the condition may still
be fatal due to persistent secondary injury mechanisms
such as the development of cerebral edema [168]. The type
and severity of edema may be influenced by the duration
and severity of ischemia and reperfusion status, amongst
other factors, and may also differ between the core and the
penumbra of the stroke lesion.
Cerebral edema is a major cause of clinical deterioration
within the first 24 h, is the leading cause of death within the
first week, and is a predictor of poor outcome following stroke
[30]. Clinical studies report that it is maximal between 1 and
3 d following stroke [18], whilst experimental studies report
its presence as early as 15mins after the onset of vascular
occlusion [169]. The presence of vasogenic edema is of par-
ticular concern, not only because it increases brain volume,
but also because in the setting of vascular recanalization, it
increases risk of hemorrhagic transformation from damaged
blood vessels and excess fluid accumulation [170].
7.1. Substance P in Stroke. To date, few groups have investi-
gated SP in cerebral ischemia [171], and only our research
group has explored the role of neurogenic inflammation
following stroke [172–175]. Our own studies have recently
shown that SP is increased following experimental ischemic
stroke, indicative of neurogenic inflammation. Specifically,
increased SP immunoreactivity was observed within penum-
bral tissue at 24 h following stroke, being particularly marked
in perivascular tissue. Such an increase in SP was confirmed
through SP ELISA of the ischemic hemisphere [174]. The
increase in SP was associated with marked disruption to the
BBB, as evidenced by increased Evan’s blue extravasation into
the brain parenchyma at 24 h after stroke, thus, supporting
previous observations of a delayed opening of the BBB [176].
The increased BBB permeability was observed in the setting
of profound cerebral edema, suggesting that the edema had
a vasogenic component [174]. Furthermore, profound and
persistent functional deficits with respect to motor, sensory,
and neurological function were observed [174].
A role for SP in clinical stroke has also been docu-
mented by Bruno and colleagues [177], suggesting that there
may be a role for neurogenic inflammation in this disease
pathogenesis. They observed that patients with transient
ischemic attack and complete stroke showed elevated serum
SP when compared to the control group [177]. Interestingly,
individuals with transient ischemic attack showed a greater
elevation than complete stroke [177].
Early studies reported that hypoxia of the rabbit carotid
body increased SP release as a function of the severity of the
hypoxic insult [178]. This finding suggested that SP release
may be a tissue response to hypoxia/ischemia. Consistent
with this, capsaicin pre- or posttreatment was shown to
confer protection from neonatal hypoxia-ischemia injury
with a reduction in infarct volume and apoptosis, in addition
to improved vascular dynamics [179].
Given the clear increase in SP that has been docu-
mented in both experimental and clinical stroke studies,
NK1 tachykinin receptor antagonists have been investigated
for their potential utility in reducing BBB dysfunction and
vasogenic edema in the setting of ischemic stroke. Yu and
colleagues [171] reported a reduction in infarct volume and
an improvement in neurological outcome asmeasured at 24 h
poststroke following administration of the NK1 tachykinin
receptor antagonist SR-14033. Recently, our group has
extended these initial observations and extensively character-
ized the effect of NK1 tachykinin receptor antagonist treat-
ment in experimental ischemic stroke. Specifically, we have
shown that intravenous NK1 antagonist treatment adminis-
tered 4 hours following stroke resulted in decreased evidence
of cerebral edema [174]. Furthermore, when combined with
the current standard clot dissolution treatment, tissue plas-
minogen activator (tPA), NK1 antagonist treatment resulted
in equal or better performance in functional outcome tests
when compared to NK1 antagonist or tPA alone [175].
7.2. Substance P in Subarachnoid Hemorrhage. Similar to
ischemic stroke, altered SP expression has been reported fol-
lowing SAH. Perivascular SP expression was increased in two
models of SAH, injection of autologous blood into the prechi-
asmatic cistern and following puncture of themiddle cerebral
artery to cause an endogenous bleed [180]. However, NK1
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tachykinin receptor antagonist treatment was unable to ame-
liorate the raised ICP, cerebral edema, or impaired functional
outcome that resulted in either of these models of SAH [180].
A possible reason for this is that the pathogenesis of SAH
differs greatly from ischemic stroke, in whichNK1 tachykinin
receptor antagonists have shown promise. SAH presents less
opportunity for therapeutic intervention, due to the mass
effect of the bleed, such that therapeutic interventions that
act to modulate the permeability of BBB have limited effects.
Thus, the functional deficits that result from SAH may be
more related to the space occupying blood and damage from
its breakdown products rather than to cerebral edema.
7.3. Calcitonin Gene-Related Peptide in Ischemic Stroke. The
well-established vasodilatory actions of CGRP have led
researchers to postulate that it may play a protective role to
promote cerebral blood flow following ischemic stroke. This
effect was demonstrated in a rat model of middle cerebral
artery reperfusion stroke. Following injury, treatment with
CGRP administered at the beginning of reperfusion resulted
in a reduction of arterial blood pressure, decreased the infarct
volume, and ameliorated the increased BBB permeability
subsequently inhibiting cerebral edema formation [181, 182].
Along with the vasodilatory actions of CGRP, the mech-
anism of neuroprotection following ischemic reperfusion
stroke may be through modulation of water channels and
other elements of the BBB. As such, in two studies using
the middle cerebral artery reperfusion model of rodent
stroke, CGRP treatment resulted in decreased aquaporin 4
mRNA and protein expression [181, 182]. In conjunction,
the reduction in tight junction proteins normally associated
with stroke was ameliorated, along with reduced evidence of
ultrastructural damage of endothelial cells [181, 182]. Simi-
larly, increased expression of basic fibroblast growth factor
has been found following experimental ischemic reperfusion
stroke treated with CGRP, which likely acts to improve the
structural integrity of the BBB basement membrane [182].
Furthermore, the neuroprotective effects of leptin in a mouse
model of middle cerebral artery occlusion and reperfusion
injury have been shown to bemediated by CGRP, resulting in
increased blood flow and once again reduced infarct volume
[183]. Thus, CGRP may be a promising treatment to improve
functional outcome following cerebral ischemia through
multiple actions on the BBB to reduce the severity of injury.
7.4. Calcitonin Gene-Related Peptide in Subarachnoid Hem-
orrhage. Akin to ischemic stroke, CGRP is thought to be
beneficial following SAH. CGRP has been measured in the
cranial venous outflow of 34 patients following SAH and was
found to be elevated when compared to the control group,
although there was no change in SP levels [184]. In contrast,
following subarachnoid hemorrhage, autopsy brain concen-
trations of CGRP were reduced in comparison with controls
in the location of the proximal middle cerebral artery [185].
Therefore, SAH results in modulation of CGRP levels in both
the blood and the brain. A possible reason for the differential
effectsmay be that the study in which CGRPwas elevated was
conducted on patients who had survived their SAH, whilst
decreased CGRP was evident following the fatal condition.
Thus, the severity of SAH may determine the extent and
direction of changes in CGRP. It is postulated that exhaustion
of CGRP may be involved in vasospasm, which is most com-
mon following severe SAH, and is often a fatal complication.
CGRP has been tested in both clinical SAH patients and
in experimental models of SAH showing protection from
abnormal blood vessel contraction. Intravenous administra-
tion of human 𝛼CGRP significantly inhibited vasoconstric-
tion in comparison to that evident prior to infusion in 5
patients [186]. Similarly, when rabbit basilar artery strips were
isolated following experimental subarachnoid hemorrhage,
responsiveness to in vitro application of CGRP to induce
blood vessel relaxation was impaired when compared to
those from the control group [101]. This result suggests that
increased CGRP levels are required in stroke patients. It
is likely that CGRP treatment may hold promise for the
prevention of complications associated with subarachnoid
hemorrhage.
Taken together, both animal and clinical studies show
that neurogenic inflammation plays an integral role in the
pathogenesis of both ischemic stroke and SAH. However,
there is a differential effect of inflammatory neuropeptides
in these conditions. The role of neurogenic inflammation in
ICH has not been widely investigated, although it is likely
that, similar to SAH, the edema component of this condition
may not contribute as significantly as blood volume to the
development of neurological deficits. There is evidence of SP
mediation of many deleterious secondary injurymechanisms
following ischemic reperfusion injury, including cerebral
edema formation.Thus theNK1 receptor is a promising target
for pharmacological manipulation to improve patient out-
comes. In contrast, SP does not seem to play a significant role
in the immediate injury following subarachnoid SAH.CGRP-
induced vasodilation may improve blood flow to hypoxic
brain tissue during cerebral ischemia and prevent vasospasm
following subarachnoid hemorrhage. This indicates that spe-
cific neurogenic inflammatory mediators need to be targeted
in different ways to optimize treatment following stroke.
8. Bacterial Meningitis
Meningitis is characterized by infection and subsequent acute
inflammation of the meninges that cover the outside of
the brain. The most common causative infectious agent is
bacteria, specifically Neisseria meningitidis and Streptococcus
pneumoniae. There is a marked adult incidence of bacte-
rial meningitis but generally children are most susceptible
[187]. Meningitis is associated with CNS symptoms such as
neck stiffness, headache, photophobia, phonophobia, altered
consciousness, and neurological state, as well as systemic
signs of inflammation such as fever, nausea, and vomiting.
Additionally, individual bacteria typesmay be associatedwith
specific features, for example,Neisseriameningitidis produces
a characteristic rash.
The introduction of vaccinations against specific strains
of bacteria has substantially reduced the incidence of this
meningitis [188]. Despite this, the availability of antibiotics to
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combat bacterial infection of the meningitis remains a med-
ical emergency due to the close proximity of inflammation
to neurological tissue. This poses a critical threat to brain
tissue, not only due to the presence of bacteria, but also
the contribution of secondary injury processes. Specifically,
inflammatory processes are associated with increased per-
meability of the BBB and cerebral edema, which worsen
the prognosis associated with this disease [6]. Furthermore,
cytokine production and leukocyte accumulation are key
features in the pathogenesis of bacterial meningitis.
Currently, anti-inflammatory agents are used in an
attempt to combat the symptoms of meningitis, although the
dose and duration of treatment are limited by deleterious
side effects of the commonly used drugs like the synthetic
corticosteroid, dexamethasone. Therefore, alternative ther-
apeutic agents that combat secondary injury and inflam-
matory processes are attractive targets for investigation.
Neurogenic inflammation may be a worthy target given its
documented role in BBB permeability and cerebral edema in
the setting of acute brain injury and stroke. Specifically, NK1
tachykinin receptor antagonists are able to block neurogenic
inflammation by modulating neuropeptide action. In the
setting of meningitis, this may prevent deleterious changes in
diameter and permeability of cerebral blood vessels and thus
leukocyte infiltration and edema formation.
8.1. Substance P in Meningitis. In vitro, SP has been shown
to increase the production of inflammatory cytokines by
astrocytes and microglia when exposed to Neisseria menin-
gitidis and Borrelia burgdorferi gram-negative bacteria [189].
Similarly, SP treatment of microglia in vitro, which were
exposed to the gram-negative Borrelia burgdorferi bacteria,
results in augmented secretion of prostaglandin E2 [190].This
effect was ameliorated by NK1 tachykinin receptor antagonist
treatment and in NK1 knockout cell lines [190]. Furthermore,
microglial cells respond to the presence of the gram-positive
bacteria Streptococcus pneumoniae with upregulation of NK1
receptors by this cell type [191].These results suggest that NK1
antagonist treatment may act to inhibit many inflammatory
processes associated with bacterial meningitis that cause
substantial tissue damage and worsen outcome.
Positive results from in vitro studies led to in vivo
experiments to determine the effectiveness of NK1 receptor
antagonists in experimental mouse models of both gram-
positive and gram-negative bacterial meningitis. Intrac-
erebral inoculation of Neisseria meningitidis and Borrelia
burgdorferi into C57BL/6 mice resulted in increased inflam-
matory cytokine and decreased immunosuppressive cytokine
secretion, resulting in a substantially proinflammatory envi-
ronment [189]. Correspondingly, intracerebral inoculation of
female C57BL/6 mice with Streptococcus pneumoniae caused
a similar pattern of cytokine expression along with gliosis,
demyelination, and increased BBB permeability [191]. These
features were abolished with both NK1 antagonist treatment
and in NK1 knockout mice [189, 191]. Therefore, NK1 antag-
onist treatment may be able to limit infection-associated
inflammation and subsequent edema formation through its
ability to inhibit inflammatory cytokine secretion and mod-
ulate the permeability of the BBB. The results suggest that in
the future, this class of agents could be used as an alternative
to classical anti-inflammatory drugs like dexamethasone.
However, the effect of NK1 receptor antagonist treatment has
only been demonstrated in experimental animal models of
meningitis; thus, further investigation into the role of SP in
the human condition is required.
8.2. Calcitonin Gene-Related Peptide in Meningitis. The proi-
nflammatory nature of meningitis makes CGRP a likely
candidate in the pathogenesis of associated vascular changes,
although there has been limited investigation into this area.
Nevertheless, patients with acute bacterial meningitis and
sepsis have shown evidence of increased CGRP in arterial
blood samples [192]. Therefore, the possible role of CGRP in
the inflammatory response of bacterial meningitis warrants
additional examination.
9. Conclusion
Acute injury to the brain and spinal cord is associated
with a number of deleterious secondary injury processes
of which altered vascular permeability and tissue swelling
are of particular concern. This is further compounded by
the lack of effective therapies. However, the inhibition of
neurogenic inflammation may provide a novel alternative
therapy for the treatment of barrier dysfunction and tissue
swelling in the setting of acute CNS injury. Experimental
studies of TBI and stroke have shown that blocking the
action of SP with an NK1 tachykinin receptor antagonist
produces profound reductions in BBB permeability, cerebral
edema, and functional deficits. Studies of NK1 tachykinin
receptor antagonists in SCI, meningitis, and hemorrhagic
stroke are ongoing, but early results suggest that neurogenic
inflammation does play a role in these pathologies, albeit a
less pronounced role than in TBI and stroke. CGRP may be
anotherworthy target alongside SPwith experimentalmodels
of both hemorrhagic and ischemic stroke models showing
benefits of CGRP treatment. Further investigations on the
role of neurogenic inflammation and the neuropeptides SP
and CGRP in the barrier dysfunction and tissue swelling that
are associated with acute brain and spinal cord injury are
ongoing, and given the encouraging results to date, they are
certainly warranted.
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